IDO1 and myeloid sarcoma: In the attempt to shed light on the role of the IDO pathway in MS we analyzed IDO, IFN-γ, and IDO enzyme activity in PBMCs of RR-MS patients undergoing clinical relapse before and after the initiation of glucocorticoids (GC) therapy.